Product Images Leflunomide
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Leflunomide NDC 62332-062 by Alembic Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
leflunomide 10 mg
This is a medicine called Leflunomide. Each tablet contains 10 mg of Leflunomide USP, with dosage and administration instructions provided on the package insert. It should be stored at room temperature between 25°C and 30°C, protected from light and out of reach of children. This is a tamper-evident package, with child-resistant caps that should be tightly closed after use. The manufacturer is Alembic Pharmaceuticals Limited, headquartered in Gujarat, India, and it is manufactured for Alembic Pharmaceuticals Inc. in the USA. The medicine comes in a pack of 30 tablets and the label includes the NDC code and manufacture date.*
leflunomide 20 mg
This text is for a medicine called Leflunomide. Each tablet contains 20 mg of Leflunomide USP. The package insert contains information about dosage and administration. The medicine should be stored at a temperature of 25°C (77°F) with excursions permitted to 1510 30°C (59-86°F). It should be protected from light and kept out of reach of children. The package has a tamper-evident safety seal, and a child-resistant cap. The medicine is manufactured by Alembic Pharmaceuticals Limited in Gujarat, India for Alembic Pharmaceuticals, Inc., based in Bedminster, NJ, USA. The package contains 30 tablets and its NDC is 62332-062-30. The text also includes manufacturing and expiration dates, as well as a coding area.*
Figure 1 - leflunomide figure1
The text appears to be a chart showing the percentage of patients who responded to a treatment called "ACR 20" at different trial periods (6 and 12 months). The treatment involved the drug Methotrexate, with a comparison to a placebo. The chart seems to provide percentages for three separate trials labeled 1, 2, and 3. The chart also includes a scale representing the percentage of responders and a label for "LMP" or possibly "LMPPL."*
Figure 2 - leflunomide figure2
This text appears to be a chart or graph related to a medical or scientific study, showing the percentage of patients who responded to treatment (ACR responders) over time in a trial labeled "Trial 1". Without further context or the ability to see the visual components of the graph/chart, it is difficult to provide a more specific description.*
Figure 3 - leflunomide figure3
Figure 4 - leflunomide figure4
This is a description of a measure called "Change in Functional Ability Measure" that shows improvement over a period of 12 months in the L M P L s P L™ foos. The improvement is indicated by a symbol and is measured by the HAQ Disability Index. There are also some numerical values indicated as 045, 044, and 06.*
Structure - leflunomide metabolite
Structure - leflunomide structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.